Merck KGAA Ramps Up Immuno-Oncology R&D To Close Ground On Rivals
This article was originally published in The Pink Sheet Daily
Executive Summary
The German company is looking to strengthen its cancer immunotherapy portfolio by establishing a dedicated research unit and increasing business development in the field.
You may also be interested in...
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Merck KGAA Begins Transformation Effort By Closing Geneva Site
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.